TenNor Completed 264 Million RMB Series D Financing
March 30, 2022,TenNor Therapeutics (Suzhou) Limited announced the completion of 264 million RMB series D financing, led jointly by Yanchuang Capital and GTJA Investment, followed by Galaxy Capital, Bison Capital, Guolian Xinchuang, Zhongnuo Venture Capital and Oriza Holdings. The capital raised will be used to advance late-stage clinical development of key products.